Bliss GVS Pharma Limited has issued a clarification regarding a news item published by CNBC Awaaz on February 13, 2026. The news item suggested a potential acquisition of Bliss GVS Pharma by Anupam Rasayan. The company has stated that the news appears to be speculative and does not originate from any official communication. As of the current date, no decision, arrangement, or approval has been finalized or crystallized by the promoters of Bliss GVS Pharma concerning the reported acquisition. Bliss GVS Pharma emphasized that no information or development warrants disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company reiterated its commitment to being a well-governed and compliant entity, ensuring timely and appropriate disclosures to the stock exchanges as required by applicable laws and SEBI regulations. Investors are advised to rely solely on official disclosures made by the company. This clarification is intended to prevent the establishment of a false market sentiment.
